Cellectis Publishes Creation of `Smart CAR T-Cells` for Potentially Safer, More Effective Treatments for Cancer in Nature Communications
(WorldNews France)

Cellectis Publishes Creation of `Smart CAR T-Cells` for Potentially Safer, More Effective Treatments for Cancer in Nature Communications 13 Nov 2019 22:30 CET Company Name CELLECTIS ISN FR0010425595 Market Euronext Growth Symbol ALCLS Cellectis Researchers Build CAR T-Cells Able to Sense and React to Their Environment by Secreting Therapeutic Proteins That Improve Their Ability to Fight Cancerous Cells Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today a paper published in Nature Communications that describes a...